My perspective is that the program continues towards...

My perspective is that the program continues towards commercialisation.

Yes, the passing of a patient is tragic news, but did anyone really expect 100% survival when we started the trial in late 2022? The study did indicate that one particular patient was not achieving the pleasing results of the others. The fact he/she had Bulbar MND may have influenced the outcome.

The market is easily spooked and some investors on this thread seem to be piling on "The Sky is Falling" bandwagon and it is not helpful.

The ultimate objective is to provide a safe therapy to extend the lifespan of MND/ALS patients. Treating with an optimal dose as early as possible after diagnosis will potentially demonstrate achievement of stability and benefit to patients in the upcoming Phase2/3 adaptive study. Our preparations are in order with 1m tablets slated for production.

The key to the whole endeavour is funding. The granting of Orphan Drug Designation will bring potential partnerships and funding opportunities into a much sharper focus.

Keep calm and carry on is a message worth observing...